In This Article:
Anika Therapeutics (NASDAQ:ANIK) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$38.8m (down 6.5% from 3Q 2023).
-
Net loss: US$29.9m (loss widened by 355% from 3Q 2023).
-
US$2.03 loss per share (further deteriorated from US$0.45 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Anika Therapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) also missed analyst estimates significantly.
Looking ahead, revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 21%.
Performance of the American Biotechs industry.
The company's shares are down 30% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Anika Therapeutics' balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.